2Spieker-Polet H,Sethupathi P,Yam PC,et al.Rabbit monoclonal antibodies:generating a fusion partner to produce rabbit-rabbit hybridomas[J].Proc Natl Acad Sci USA,1995,92(20):9348-9352. 被引量：1
3Li J,Sai T,Berger M,et al.Human antibodies for immunotherapy development generated via a human B cell hybridoma technology[J].Proc Natl Acad Sci USA,2006,103(10):3557-3562. 被引量：1
4Reichert JM,Rosensweig CJ,Faden LB,et al.Monoclonal antibody successes in the clinic[J].Nat Biotechnol,2005,23(9):1073-1078. 被引量：1
5Rohrbach P,Broders O,Toleikis L,et al.Therapeutic antibodies and antibody fusion proteins[J].Biotechnol Genet Eng Rev,2003,20:137-163. 被引量：1
6Reichert JM.Therapeutic monoclonal antibodies:trends in development and approval in the US[J].Curr Opin Mol Ther,2002,4(2):110-118. 被引量：1
7Wu AM,Senter PD.Arming antibodies:prospects and challenges for immuno-conjugates[J].Nat Biotechnol,2005,23(9):1137-1146. 被引量：1
8Trikha M,Yan L,Nakada MT.Monoclonal antibodies as therapeutics in oncology[J].Curr Opin Biotechnol,2002,13(6):609-614. 被引量：1
9Adams GP,Weiner LM.Monoclonal antibody therapy of cancer[J].Nat Biotechnol,2005,23(9):1147-1157. 被引量：1
10Karpas A,Dremucheva A,Czepulkowski BH.A human myeloma cell line suitable for the generation of human monoclonal antibodies[J].Proc Natl Acad Sci USA,2001,98(4):1799-1804. 被引量：1
3VERGARA-JIMENEZ J, TRICOCI P. Safety and efficacy of abciximab as an adjunct to percutaneous coronary inter- vention [ J ]. Vasc Health Risk Manag, 2010,6 ( 3 ) : 39 - 45. 被引量：1
4KANG S, ROH Y J. Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration[ J ]. Jpn J Ophthalmol,2011,55 (2) : 123 - 127. 被引量：1
5GOEL N, STEPHENS S. Certolizumab pegol [ J ]. MAbs, 2010,2(2) :137 - 147. 被引量：1
7GIBSON C M, PRIDE Y B. Myocardial infarct size reduc- tion with pexelizumab: The role of chance is patently clear[ J ]. JACC Cardiovasc Imaging, 2010,3 ( 1 ) : 61 - 63. 被引量：1
8HOLLIGER P, PROSPERO T, WINTER G, "Diabodies" : small bivalent and bispecific antibody fragments [ J ]. Proc Natl Acad Sci U S A,1993,90(14) :6A.A.A. -6448. 被引量：1
9LUM L G, DAVOL P A, LEE R J. The new face of bispe- cific antibodies: targeting cancer and much more [ J ]. Exp Hemato1,2006, 34( 1 ) : 1 - 6. 被引量：1
10FISCHER N, LEGER O. Bispecific antibodies: Mole- cules that enable novel therapeutic strategies [ J ]. Patho- biology,2007,74( 1 ) :3 - 14. 被引量：1
